Neuregulin-1 beta (NRG-1) is a growth and survival factor in several organ systems, and is critical for cardiac development. In the adult heart NRG-1 is a stress-activated mediator of cardiac repair after injury. Parenteral administration of recombinant NRG-1 enhances survival and improves cardiac function in chemotherapeutic, viral, myocardial infarction (Ml) and rapid-pacing induced heart failure models in mouse, rat and dog. Acorda Therapeutics owns the recombinant NRG-1 Glial Growth Factor 2 (GGF2) which is being developed for treatment of heart failure and demyelinating diseases. The central hypothesis of this proposal is that GGF2 can be used to treat systolic heart failure. In this stage 1 CTRIP proposal, we are partnering with Acorda Therapeutics to advance this effort. Acorda has completed safety studies of GGF2 in small and large animals, and plans to submit an IND for use of GGF2 in treatment of systolic heart failure. Critical animal work is necessary to determine minimal effective dose of GGF2 for cardiac recovery after myocardial infarction. Further work in small and large animals will be carried out to develop noninvasive imaging strategies to determine biological effects of GGF2 in the myocardium. Following successful IND submission, we will carry out a phase 1 human trial in persons with systolic heart failure. Noninvasive imaging and peripheral biomarker studies will be examined in conjunction with the phase 1 trial to determine minimal biologically efficacious dose. We have brought together a team of consultants from four Institutions to help guide the planning of a multicenter randomized placebo controlled study to be proposed for the stage 2 application that will test the hypothesis that GGF2 will induce sustained improvements in cardiac function in persons with systolic heart failure.
Heart failure is a common condition that results in chronic illness and early death, and is often caused by weakening of the heart. We propose to carry out a series of experiments, including a safety study in people with a new therapy for weak heart muscles. If successful this therapy has the potential to save the lives of people with heart failure.
|Ryzhov, Sergey; Robich, Michael P; Roberts, Daniel J et al. (2018) ErbB2 promotes endothelial phenotype of human left ventricular epicardial highly proliferative cells (eHiPC). J Mol Cell Cardiol 115:39-50|
|Huang, Zhihong; Sawyer, Douglas B; Troy, Erika L et al. (2017) Species-specific effects of neuregulin-1? (cimaglermin alfa) on glucose handling in animal models and humans with heart failure. Toxicol Appl Pharmacol 332:92-99|
|Stephenson, Matthew K; Lenihan, Sean; Covarrubias, Roman et al. (2016) Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix. J Vis Exp :|
|Galindo, Cristi L; Ryzhov, Sergey; Sawyer, Douglas B (2014) Neuregulin as a heart failure therapy and mediator of reverse remodeling. Curr Heart Fail Rep 11:40-9|
|Galindo, Cristi L; Kasasbeh, Ehab; Murphy, Abigail et al. (2014) Anti-remodeling and anti-fibrotic effects of the neuregulin-1? glial growth factor 2 in a large animal model of heart failure. J Am Heart Assoc 3:e000773|
|Hill, Michael F; Patel, Amish V; Murphy, Abigail et al. (2013) Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1? improves left ventricular function, gene and protein expression in rats after myocardial infarction. PLoS One 8:e55741|
|Cote, Gregory M; Sawyer, Douglas B; Chabner, Bruce A (2012) ERBB2 inhibition and heart failure. N Engl J Med 367:2150-3|
|Odiete, Oghenerukevwe; Hill, Michael F; Sawyer, Douglas B (2012) Neuregulin in cardiovascular development and disease. Circ Res 111:1376-85|
|Sawyer, Douglas B; Caggiano, Anthony (2011) Neuregulin-1? for the treatment of systolic heart failure. J Mol Cell Cardiol 51:501-5|